Epidermal growth factor receptor is a preferred target for treating Amyloid-β-induced memory loss

Lei Wang, Hsueh Cheng Chiang, Wenjuan Wu, Bin Liang, Zuolei Xie, Xinsheng Yao, Weiwei Ma, Shuwen Du, Yi Zhong

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Current understanding of amyloid-β (Aβ) metabolism and toxicity provides an extensive list of potential targets for developing drugs for treating Alzheimer's disease. We took two independent approaches, including synaptic-plasticity-based analysis and behavioral screening of synthetic compounds, for identifying single compounds that are capable of rescuing the Aβ-induced memory loss in both transgenic fruit fly and transgenic mouse models. Two clinically available drugs and three synthetic compounds not only showed positive effects in behavioral tests but also antagonized the Aβ oligomers-induced activation of the epidermal growth factor receptor (EGFR). Such surprising converging outcomes from two parallel approaches lead us to conclude that EGFR is a preferred target for treating Aβ-induced memory loss.

Original languageEnglish
Pages (from-to)16743-16748
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume109
Issue number41
DOIs
Publication statusPublished - 2012 Oct 9

All Science Journal Classification (ASJC) codes

  • General

Fingerprint Dive into the research topics of 'Epidermal growth factor receptor is a preferred target for treating Amyloid-β-induced memory loss'. Together they form a unique fingerprint.

  • Cite this